Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists

Open access
Fruchart, Jean-Charles · 2013 · Cardiovascular Diabetology

Abstract

Dyslipidemia is a major risk factor for cardiovascular (CV) disease - the primary cause of death, worldwide. Although reducing levels of low-density lipoprotein-cholesterol can significantly reduce CV risk, a high level of residual risk persists, especially in people with obesity-related conditions, such as metabolic syndrome and type 2 diabetes mellitus. Peroxisome proliferator-activated receptor alpha- (PPARα-) agonists (e.g. fibrates), play a central role in the reduction of macro- and microvascular risk in these patients. However, the currently available fibrates are weak (PPARα-agonists) with limited efficacy due to dose-related adverse effects. To address this problem, a new generation of highly potent and selective PPARα-modulators (SPPARMα) is being developed that separate the benefits of the PPARα-agonists from their unwanted side effects. Among these, aleglitazar (a dual PPARα/γ agonist) and GFT505 (a dual PPAR α/δ agonist) have recently entered late-phase development. Although both compounds are more potent PPARα-activators than fenofibrate in vitro, only aleglitezar is more effective in lowering triglycerides and raising high-density lipoprotein-cholesterol (HDL-C) in humans. However, it is also associated with a potential risk of adverse effects. More recently, a highly potent, specific PPARα-agonist (K-877) has emerged with SPPARMα characteristics. Compared to fenofibrate, K-877 has more potent PPARα-activating efficacy in vitro, greater effects on triglycerides- and HDL-C levels in humans, and a reduced risk of adverse effects. If successful, K-877 has the potential to supersede the fibrates as the treatment of choice for patients with residual CV risk associated with metabolic syndrome and type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1475-2840-12-82

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 PPAR-agonists have the potential to trigger different biological responses via the same receptor[34].
Figure 1 PPAR-agonists have the potential to trigger different biological responses via the same receptor[34].CC BY · PubMed Central
Figure 2 SPPARMα characteristics. ALT alanine aminotransferase; Apo apolipoprotein; FGF-21 fibroblast growth factor 21; γGT γ-glutamyl transpeptidase; HDL high-density lipoprotein; NASH/NASFL non-alcoholic steatohepatitis/fatty liver disease; NR nuclear receptor; TG triglyceride.
Figure 2 SPPARMα characteristics. ALT alanine aminotransferase; Apo apolipoprotein; FGF-21 fibroblast growth factor 21; γGT γ-glutamyl transpeptidase; HDL high-density lipoprotein; NASH/NASFL non-alcoholic steatohepatitis/fatty liver disease; NR nuclear receptor; TG triglyceride.CC BY · PubMed Central
Figure 3 Chemical structures of PPARα agonists.
Figure 3 Chemical structures of PPARα agonists.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 196

Metadata

Authors
Fruchart, J.-C.
Affiliations
Fondation Coeur et Artères (FR)
Corresponding author
Fruchart, Jean-Charles
Venue
Cardiovascular Diabetology
Published
2013
Volume
12
Issue
1
Pages
82
ISSN
1475-2840 (ISSN-L)
OpenAlex
W2144259092
Cited by
189
References
54
Citations by year
2026: 7 · 2025: 12 · 2024: 14 · 2023: 18 · 2022: 10 · 2021: 15 · 2020: 18 · 2019: 15 · 2018: 22 · 2017: 16 · 2016: 13 · 2015: 11 · 2014: 17 · 2013: 1
FWCI
1.32
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords
PPARα agonist, fibrates, aleglitazar, dyslipidemia, residual cardiovascular risk, metabolic syndrome, type 2 diabetes, triglycerides, HDL cholesterol, PPARα/γ dual agonist, fenofibrate, adverse effects
MeSH terms
Hypolipidemic Agents, Benzoxazoles, Butyrates, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Risk Factors, PPAR alpha, PPAR gamma, Dyslipidemias, Fibric Acids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists. https://app.cochat.ai/papers/10.1186/1475-2840-12-82
The paper
Fruchart, J.-C. (2013). Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovascular Diabetology. https://doi.org/10.1186/1475-2840-12-82

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.